4314
Pharmacoeconomic assessment of hepatoprotectors used for prevention of developing post-resection acute liver failure after extensive hemihepatectomy due to colorectal cancer metastases
During the current study, a pharmacoeconomic assessment of liver failure prevention after using Remaxol® (succinic acid, N-methylglucamine, inosine, methionine, nicotinamide – hereinafter SMIMN) vs. ademetionine was performed in patients with extensive liver resection. As a primary efficacy endpoint, a number of patients needed to treat (NNT) to reach a Child-Pugh Grade A liver functional state was used while analyzing therapeutic efficacy. In the clinical study, Khoronenko et al. demonstrated, that efficacy of SMIMN was higher than ademetionine in restoring liver functional state. On Day 5 and 12 after liver resection cost-effectiveness ratio measured in SMIMN vs. ademetionine groups was 39,624 vs. 96,634 Rub and 34,661 vs. 55,236 Rub, respectively, favoring conclusion that use of SMIMN exhibiting higher efficacy is a dominant approach for preventing acute liver failure (ALF) after extensive liver resection. Budget Impact Analysis revealed that budget savings after treatment with SMIMN vs. ademetionine were 11,831,861 Rub per 1,083 patients, and within a fixed budget, it allowed additionally to treat up to 427 patients
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF
Bibliography link:
Pochuprina A.A., Kulikov A.Yu. Pharmacoeconomic assessment of hepatoprotectors used for prevention of developing post-resection acute liver failure after extensive hemihepatectomy due to colorectal cancer metastases // Pharmacoeconomics: theory and practice. - 2016. - Vol.4, №3. - P.62-68 DOI: https://doi.org/10.30809/phe.3.2016.3
Comments0